PPT-TDF-FTC versus Placebo as HIV PrEP for Transgender Women

iPrEx Trial Substudy TDFFTC versus Placebo as HIV PrEP for Transgender Women iPrEx Substudy Study Design Source Deutsch MB et al Lancet HIV 20152e5129 Background Subgroup analysis of the . An HIV pre-exposure prophylaxis trial in Thailand: . participant adherence and study results . National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Division of HIV/AIDS Prevention. A collaborative project involving: The Bangkok Metropolitan Administration, the. based . PrEP. technologies in women : . what do we currently know?. Linda-Gail Bekker . The Desmond Tutu HIV Centre. University of Cape Town.. Expanding HIV Prevention Options for Women.. The need for a female initiated, managed and controlled prevention methodology.. de . l’étude. Critère. principal . –. puissance . statistique. : pour 64 infections par le VIH-1, puissance de 80 % pour . détecter. . une. diminution relative de 50 % de . l’incidence. 4. . (b) . Risks and Side Effects. Overview. Resistance. Resistance has occurred rarely when PrEP initiated during acute HIV infection. M184V. Prevent by not initiating/re-initiating PrEP during acute HIV infection. Efficacy and the importance of adherence. Joanne . Stekler. , MD MPH. August 20, 2015. Key HIV . PrEP. Trials Using Oral . Tenofovir. (TDF) or . Tenofovir-Emtricitabine. (TDF-FTC). Study. Study Population. Kiat. . Ruxrungtham. Professor of Medicine, . Chulalongkorn University; and. HIV-NAT, Thai Red Cross AIDS Research Center. Three Decades of HIV/AIDS . Learning and the Future. Mid 1990. 1981. 2012 - 2014. Estudio GS-US-311-1089 . Estudio GS-US-366-1216 . Estudio GS-US-366-1160 . . Diseño. Endpoints. Primario: proporción de pacientes . con C. V . < 50 c/mL a S48 (ITT, . snapshot. ) ; no inferioridad si el margen inferior de IC95% de dos colas para la diferencia = - 8%, poder 85%. Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV: ADVANCE and NAMSAL trials Andrew Hill, Francois Venter, Eric Delaporte , Simiso Sokhela, Charles amoe@mednet.ucla.edu. UCLA CARE clinic/NEVHC Van Nuys . 21 June 2014. I do not have any financial arrangements or affiliations with commercial sponsors which have direct interest in the subject matter. Study GS-366-1216. Switch from TDF to TAF, each with RPV and FTC. Study GS-366-1216: Design. Source: . Orkin. C et al. Lancet HIV. 2017;4:e195-e204.. *. NOTE. :. of 632 participants randomized, 2 were never treated (630 individuals treated). Last Updated: October 6, 2023. Prepared by:. David H. Spach, MD. Brian R. Wood, MD. Oral Cabotegravir (Optional) . Cabotegravir Injectable (IM). Cabotegravir for HIV PrEP. INSTI. 30 mg. Oral Cabotegravir . ROCKET II. Switching to TDF-FTC from ABC-3TC . for Hyperlipidemia . ROCKET II. : Study Design. Source: Behrens G, et al. . Antivir. . Ther. . . 2012;17:1011-20.. TDF-FTC + LPV-RTV. (. n = . 42). ABC-3TC + LPV-RTV. ADVANCE. . Design. Primary endpoint. Proportion of patients with HIV RNA < 50 c/mL at W48, ITT-E snapshot analysis ; non-inferiority of TFA/FTC if lower margin CI for . the difference = - 10%, 80% power. RADAR Trial. Raltegravir. + Darunavir/r versus TDF-FTC + Darunavir/r. RADAR: Study Design. Source: . Bedimo. RJ, et al. . PLoS. One. 2014;9:e106221.. Darunavir QD + Ritonavir QD + Raltegravir BID .